Primary systemic amyloidosis
MONDO:0017816Primary systemic amyloidosis (PSA) is a form of AL amyloidosis caused by the aggregation and deposition of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains usually produced by a plasma cell tumor and characterized by multiple organ involvement.
Also known as: systemic AL amyloidosis, systemic Immunoglobulin Light chain amyloidosis, systemic amyloidosis
33 clinical trials for this condition and its sub-types, 22 tagged with Primary systemic amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Engineered immune cells take aim at a rare Protein-Folding disease
Cure Not yet recruitingThis trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmfu…
Phase 1/2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC